NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Tempus AI, Inc. (“Tempus” or “the Company”) (NASDAQ: TEM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Tempus securit ...

SAN DIEGO, June 18, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the "Class Period"), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI's top executives with violations of the Secur ...

NEW YORK and NEW ORLEANS, June 18, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for t ...

Core Viewpoint - A securities class action lawsuit has been filed against Tempus AI, Inc. for alleged misrepresentations and failures to disclose critical information regarding its financial practices and operations during the specified class period [1][2]. Allegations of Misconduct - The lawsuit claims that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [2] - Concerns were raised about the credibility of Tempus' joint venture with SoftBank, suggesting it appeared to involve "round-tripping" capital to artificially inflate revenue [2] - The business model of Tempus-acquired Ambry is alleged to be based on aggressive and potentially unethical billing practices, risking scrutiny and sustainability [2] - AstraZeneca reportedly reduced its financial commitments to Tempus through a questionable "pass-through payment" arrangement, raising further concerns about the company's financial integrity [2] - These issues collectively indicate weaknesses in Tempus' core operations and revenue prospects [2]. Impact of External Reports - A report from Spruce Point Capital Management highlighted numerous red flags regarding Tempus' management and financial reporting, including a history of executives cashing out before public shareholders incur losses [3] - The report also criticized the overstated AI capabilities of Tempus and pointed out aggressive accounting practices [3] - Concerns were raised about the AstraZeneca and Pathos AI deal, which warranted further scrutiny [3] - The company's recent financial guidance was seen as indicative of weaknesses in its core operations [3]. Stock Price Reaction - Following the release of the report and the ensuing allegations, Tempus' stock price dropped by $12.67 per share, or 19.23%, from $65.87 on May 27, 2025, to $53.20 on May 28, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for allegedly misleading investors regarding its financial practices and operations during the class period from August 6, 2024, to May 27, 2025 [1]. Group 1: Allegations and Issues - The complaint alleges that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [3]. - Concerns were raised about the credibility of Tempus' joint venture with SoftBank, suggesting it appeared to involve "round-tripping" capital to create revenue [3]. - The business model of Tempus-acquired Ambry is described as aggressive and potentially unethical, risking scrutiny and sustainability [3]. - AstraZeneca reportedly reduced its financial commitments to Tempus through a questionable "pass-through payment" arrangement [3]. - These issues indicate weaknesses in Tempus' core operations and revenue prospects [3]. Group 2: Impact of Reports - On May 28, 2025, a report by Spruce Point Capital Management highlighted numerous red flags regarding Tempus' management, operations, and financial reporting [4]. - The report criticized the company's actual AI capabilities as being overstated and pointed out a history of executives associated with troubled companies [4]. - It also noted signs of aggressive accounting practices and issues with the AstraZeneca and Pathos AI deal [4]. - Following the release of this report, Tempus' stock price fell by $12.67 per share, or 19.23%, from $65.87 to $53.20 [5].

Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for allegedly misleading investors regarding its business prospects and financial reporting [1][2]. Allegations - The lawsuit claims that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [2] - Concerns were raised about the credibility of Tempus' joint venture with SoftBank, suggesting it appeared to involve "round-tripping" capital to create revenue [2] - The business model of Tempus-acquired Ambry is said to be based on aggressive and potentially unethical billing practices, risking scrutiny and sustainability [2] - AstraZeneca reportedly reduced its financial commitments to Tempus through a questionable "pass-through payment" arrangement [2] - These issues indicate weaknesses in Tempus' core operations and revenue prospects [2]. Financial Impact - Following the release of a report by Spruce Point Capital Management that highlighted various red flags regarding Tempus' management and operations, the stock price fell by $12.67, or 19.23%, from $65.87 to $53.20 per share on May 28, 2025 [3][4]. Next Steps for Shareholders - Shareholders may be eligible to participate in the class action against Tempus AI, with options to serve as lead plaintiff or remain an absent class member [5].

Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for alleged securities fraud, claiming the company misrepresented its AI capabilities and financial health to investors [1][4][5]. Company Overview - Tempus AI, Inc. is publicly traded on NASDAQ under the ticker symbol TEM and has been accused of branding itself as an AI company despite limited revenue generation from AI solutions [4]. - The company primarily generates revenue through acquisitions, genomic testing, and data licensing agreements [4]. Allegations and Concerns - The lawsuit alleges that Tempus misled investors about the security and expansion of its data licensing agreements, particularly with AstraZeneca, and claimed high revenue potential from its acquisition of Ambry Genetics [4]. - A report by Spruce Point Capital Management raised concerns about Tempus' management practices, overstated AI capabilities, and aggressive accounting [5]. - Specific issues highlighted include the CEO's history of cashing out before public shareholders incur losses, connections to troubled companies, and recent revisions in financial guidance indicating weaknesses in core operations [5]. Financial Impact - Following the release of the Spruce Point Report, Tempus' stock price dropped by $12.67, or 19.23%, from $65.87 to $53.20 per share on May 28, 2025 [6]. Legal Information - Investors who purchased Tempus stock between August 6, 2024, and May 27, 2025, are eligible to participate in the class action lawsuit, with a deadline to request lead plaintiff status by August 12, 2025 [6]. Legal Representation - Shamis & Gentile, P.A. is representing the impacted investors and has a history of recovering over $1 billion for consumers affected by securities fraud [7].

Key Takeaways TEM signed a $200M three-way deal with AZN and Pathos to build a multimodal oncology foundation model. The partnership lifts TEM's total remaining contract value to over $1B as of April 2025. TEM also expanded ties with ILMN to advance molecular profiling across all major disease areas.ForTempus AI (TEM) , expanding partnerships with existing customers across each of its product lines is key to its growth. In April 2025, the AI-driven precision medicine company extended its collaboration wit ...

Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for allegedly misleading investors regarding its business prospects and financial reporting [1][2]. Allegations - The lawsuit claims that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [2] - Concerns were raised about the credibility of Tempus' joint venture with SoftBank, suggesting it appeared to involve "round-tripping" capital to create revenue [2] - The business model of Tempus-acquired Ambry is said to be based on aggressive and potentially unethical billing practices, risking scrutiny and sustainability [2] - AstraZeneca reportedly reduced its financial commitments to Tempus through a questionable "pass-through payment" arrangement [2] - These issues indicate weaknesses in Tempus' core operations and revenue prospects [2]. Management and Financial Reporting Concerns - A report by Spruce Point Capital Management highlighted several red flags regarding Tempus' management and operations, including a history of executives cashing out before public shareholders incur losses [3] - The report claims that Tempus' actual AI capabilities are overstated and that there are signs of aggressive accounting and financial reporting [3] - Issues with the AstraZeneca and Pathos AI deal were noted as requiring further scrutiny [3] - Recent financial guidance from the company suggests weaknesses in core operations [3]. Stock Price Impact - Following the news of the allegations and the report, Tempus' stock price fell by $12.67 per share, or 19.23%, from $65.87 to $53.20 on May 28, 2025 [4].

Core Insights - Tempus AI (TEM) experienced a 12.5% surge in early June, significantly outperforming the broader market due to positive investor reactions to new product launches [1][9] - The company has established a $200 million partnership with AstraZeneca and Pathos to develop a large oncology-focused foundation model, enhancing its position in AI-driven drug discovery [5][9] - Despite revenue growth, Tempus remains unprofitable, reporting an adjusted EBITDA loss of $16.2 million in Q1 2025, although this is an improvement from the previous year [14][16] Strategic Product Innovation - The xM Liquid Biopsy Assay utilizes whole-genome sequencing and fragmentomics for noninvasive monitoring of immunotherapy responses in advanced cancer patients, providing real-time treatment insights [3] - Tempus One, an AI-powered clinical assistant, has been integrated into major EHR systems, offering real-time, patient-specific insights to enhance clinical decision-making [4] Financial Performance - Year-to-date, TEM stock has increased by 83.8%, outperforming the Medical Info Systems industry and the S&P 500 [7] - The stock is currently trading at a forward 12-month price-to-sales (P/S) ratio of 7.77, which is above the industry average of 6.09, indicating it may be overvalued compared to peers [15][16] Recent Developments - The acquisition of Deep 6 AI enhances Tempus's clinical trial matching and provider analytics capabilities, expanding its provider connectivity to over 4,000 connections [6] - The partnership with AstraZeneca is expected to leverage over 300 petabytes of data, aiming to accelerate AI-driven drug discovery and diagnostics [5]